Emerging drugs for psoriatic arthritis
作者： Francesco Caso , Antonio Del Puente , Rosario Peluso , Paolo Caso , Nicolò Girolimetto
DOI: 10.1517/14728214.2016.1146679
关键词:
摘要: ABSTRACTIntroduction: The majority of Psoriatic Arthritis patients experience a good clinical response to anti-Tumor Necrosis Factor (TNF)-α therapies. However, treatment failure with anti-TNF-α can represent relevant problem.Areas covered: We review the efficacy and safety profile biological therapies that have been reported from randomized, controlled trials in phase II III available Pubmed Database for agents targeting IL-12/23p40 antibody (ustekinumab) IL-17 (secukinumab), inhibitor phosphodiesterase 4, (apremilast), JAK/STAT pathways (tofacitinib) CTLA4 co-stimulation (abatacept) Arthritis.Expert opinion: In Arthritis, main emerging drugs are represented by fully human monoclonal antibody, ustekinumab, agent IL-17, secukinumab, apremilast.Results on T cell inhibition abatacept insufficient both psoriasis PsA. vitro investigation...
sci-hub.se 参考文章(133)
Gooderham M, Papp K, Posso-De Los Rios Cj, Rubio-Gomez Ga, Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review. Skin therapy letter. ,vol. 20, pp. 1- 5 ,(2015)
Ugo Fiocco, Veronica Martini, Benedetta Accordi, Francesco Caso, Luisa Costa, Francesca Oliviero, Anna Scanu, Monica Facco, Daniele Boso, Mariele Gatto, Mara Felicetti, Paola Frallonardo, Roberta Ramonda, Lucia Piva, Renato Zambello, Carlo Agostini, Raffaele Scarpa, Giuseppe Basso, Gianpietro Semenzato, Jean-Michel Dayer, Leonardo Punzi, Andrea Doria, Transcriptional network profile on synovial fluid T cells in psoriatic arthritis Clinical Rheumatology. ,vol. 34, pp. 1571- 1580 ,(2015) , 10.1007/S10067-015-3002-2
Emma D. Deeks, Apremilast: A Review in Psoriasis and Psoriatic Arthritis Drugs. ,vol. 75, pp. 1393- 1403 ,(2015) , 10.1007/S40265-015-0439-1
Eric Ocheretyaner, Tina Zerilli, Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis. P & T : a peer-reviewed journal for formulary management. ,vol. 40, pp. 495- 500 ,(2015)
Marie Acquitter, Patrice Plantin, Ingrid Kupfer, Henri Auvinet, Thierry Marhadour, Anakinra Improves Pyoderma Gangrenosum in Psoriatic Arthritis: A Case Report Annals of Internal Medicine. ,vol. 163, pp. 70- 71 ,(2015) , 10.7326/L15-5107
KA Papp, R Kaufmann, D Thaçi, C Hu, D Sutherland, P Rohane, None, Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, dose‐comparison study Journal of The European Academy of Dermatology and Venereology. ,vol. 27, ,(2013) , 10.1111/J.1468-3083.2012.04716.X
Koichi Yanaba, Akari Sadaoka, Takenori Yonenaga, Hidehisa Saeki, Yoshinori Umezawa, Shinjiro Tojo, Toshihiro Ito, Sota Kikuchi, Kunihiko Fukuda, Hidemi Nakagawa, Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system Journal of Dermatology. ,vol. 42, pp. 1153- 1159 ,(2015) , 10.1111/1346-8138.13014
Yong Liu, Simon Zhou, James Nissel, Anfan Wu, Henry Lau, Maria Palmisano, The pharmacokinetic effect of coadministration of apremilast and methotrexate in individuals with rheumatoid arthritis and psoriatic arthritis Clinical pharmacology in drug development. ,vol. 3, pp. 456- 465 ,(2014) , 10.1002/CPDD.109
PH Schafer, A Parton, AK Gandhi, L Capone, M Adams, L Wu, JB Bartlett, MA Loveland, A Gilhar, Y-F Cheung, GS Baillie, MD Houslay, H-W Man, GW Muller, DI Stirling, Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. British Journal of Pharmacology. ,vol. 159, pp. 842- 855 ,(2010) , 10.1111/J.1476-5381.2009.00559.X
Alexander Egeberg, Usman Khalid, Gunnar Hilmar Gislason, Lotus Mallbris, Lone Skov, Peter Riis Hansen, Association of Psoriatic Disease With Uveitis: A Danish Nationwide Cohort Study JAMA Dermatology. ,vol. 151, pp. 1200- 1205 ,(2015) , 10.1001/JAMADERMATOL.2015.1986